Effect of substrate residues on the P2' preference of retroviral proteinases.

The substrate sequence requirements for preference toward P2' Glu residue by human immunodeficiency virus type 1 (HIV-1) proteinase were studied in both the matrix protein/ capsid protein (MA/CA) and CA/p2 cleavage site sequence contexts. These sequences represent typical type 1 (-aromatic*Pro-) and type 2 (-hydrophobic* hydrophobic-) cleavage site sequences, respectively. While in the type 1 sequence context, the preference for P2' Glu over Ile or Gln was found to be strongly dependent on the ionic strength and the residues being outside the P2-P2' region of the substrate, it remained preferable in the type 2 substrates when typical type 1 substrate sequence residues were substituted into the outside regions. The pH profile of the specificity constants suggested a lower pH optimum for substrates having P2' Glu in contrast to those having uncharged residues, in both sequence contexts. The very low frequency of P2' Glu in naturally occurring retroviral cleavage sites of various retroviruses including equine infectious anemia virus (EIAV) and murine leukemia virus (MuLV) suggests that such a residue may not have a general regulatory role in the retroviral life cycle. In fact, unlike HIV-1 and HIV-2, EIAV and MuLV proteinases do not favor P2' Glu in either the MA/CA or CA/p2 sequence contexts.

[1]  Irene T. Weber,et al.  Studies on the Symmetry and Sequence Context Dependence of the HIV-1 Proteinase Specificity* , 1997, The Journal of Biological Chemistry.

[2]  Irwin A. Rose,et al.  Enzyme structure and mechanism (2nd edn): by Alan Fersht, W. H. Freeman & Co., 1985. £14.95 pbk, £28.95 hbk (xxi + 475 pages) ISBN 0 7167 1615 1 , 1985 .

[3]  D. Grobelny,et al.  Selective phosphinate transition-state analogue inhibitors of the protease of human immunodeficiency virus. , 1990, Biochemical and biophysical research communications.

[4]  K. Chou,et al.  Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method , 1996, Proteins.

[5]  J. Mellors.  Closing in on human immunodeficiency virus–1 , 1996, Nature Medicine.

[6]  Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates. , 1997, European journal of biochemistry.

[7]  R. Seetharam,et al.  Human immunodeficiency virus type 1 and type 2 protease monomers are functionally interchangeable in the dimeric enzymes , 1992, Journal of virology.

[8]  D. Baltimore,et al.  Standardized and simplified nomenclature for proteins common to all retroviruses , 1988, Journal of virology.

[9]  T. Copeland,et al.  Comparison of the HIV‐1 and HIV‐2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag‐Pol polyproteins , 1991, FEBS letters.

[10]  R. Heinrikson,et al.  The differential processing of homodimers of reverse transcriptases from human immunodeficiency viruses type 1 and 2 is a consequence of the distinct specificities of the viral proteases. , 1995, The Journal of biological chemistry.

[11]  W. Howe,et al.  The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties. , 1994, Biochemistry.

[12]  H. Kräusslich,et al.  Sequential Steps in Human Immunodeficiency Virus Particle Maturation Revealed by Alterations of Individual Gag Polyprotein Cleavage Sites , 1998, Journal of Virology.

[13]  J. Condra,et al.  Clinically effective HIV-1 protease inhibitors , 1997 .

[14]  Robert W. Harrison,et al.  Stiffness and energy conservation in molecular dynamics: An improved integrator , 1993, J. Comput. Chem..

[15]  J. Louis,et al.  The effect of salt on the Michaelis Menten constant of the HIV‐1 protease correlates with the Hofmeister series , 1991, FEBS letters.

[16]  A. Wlodawer,et al.  Structure of equine infectious anemia virus proteinase complexed with an inhibitor , 1996, Protein science : a publication of the Protein Society.

[17]  I. Boros,et al.  Substrate-dependent mechanisms in the catalysis of human immunodeficiency virus protease. , 1994, Biochemistry.

[18]  A. Wlodawer,et al.  [14]Subsite preferences of retroviral proteinases , 1994 .

[19]  R. Stroud,et al.  Three-dimensional structures of HIV-1 and SIV protease product complexes. , 1996, Biochemistry.

[20]  A. Wlodawer,et al.  Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic*hydrophobic- or -aromatic*pro- cleavage sites. , 1992, Biochemistry.

[21]  A. Berger,et al.  On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.

[22]  C. Hutchison,et al.  Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. , 1991, The Journal of biological chemistry.

[23]  J. Louis,et al.  Autoprocessing of the HIV-1 protease using purified wild-type and mutated fusion proteins expressed at high levels in Escherichia coli. , 1991, European journal of biochemistry.

[24]  Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates. , 1997 .

[25]  A Wlodawer,et al.  Human Immunodeficiency Virus, Type 1 Protease Substrate Specificity Is Limited by Interactions between Substrate Amino Acids Bound in Adjacent Enzyme Subsites (*) , 1996, The Journal of Biological Chemistry.

[26]  D. Gotte,et al.  Moloney murine leukemia virus protease: bacterial expression and characterization of the purified enzyme. , 1993, Virology.

[27]  S. Misumi,et al.  The p2gag peptide, AEAMSQVTNTATIM, processed from HIV-1 Pr55gag was found to be a suicide inhibitor of HIV-1 protease. , 1997, Biochemical and biophysical research communications.

[28]  J. Louis,et al.  Kinetic and modeling studies of S3-S3' subsites of HIV proteinases. , 1992, Biochemistry.

[29]  A Wlodawer,et al.  X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Kaplan,et al.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions , 1994, Journal of virology.

[31]  N. Shen,et al.  Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arrays , 1996, Nature Medicine.

[32]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[33]  L. Tong,et al.  Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Tomasselli,et al.  Specificity of retroviral proteases: an analysis of viral and nonviral protein substrates. , 1994, Methods in enzymology.

[35]  I T Weber,et al.  Kinetic and modeling studies of subsites S4-S3' of Moloney murine leukemia virus protease. , 1994, The Journal of biological chemistry.

[36]  I. Weber,et al.  Studies on the substrate specificity of the proteinase of equine infectious anemia virus using oligopeptide substrates. , 1993, Biochemistry.

[37]  W. Farmerie,et al.  Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. , 1996, Virology.

[38]  W. Farmerie,et al.  Sensitive, soluble chromogenic substrates for HIV-1 proteinase. , 1990, The Journal of biological chemistry.

[39]  T. Copeland,et al.  Molecular characterization of gag proteins from simian immunodeficiency virus (SIVMne) , 1988, Journal of virology.

[40]  J. Louis,et al.  Structural basis for specificity of retroviral proteases. , 1998, Biochemistry.